Novel immune cell targets for efficient treatment of AML

Acute Myeloid Leukaemia (AML) is the most common form of leukaemia among adults. It has a very poor prognosis with less than 30% of patients being alive five years after diagnosis. There is thus an urgent need for novel treatment methods.

In this project we study immune cells from patients with AML in order to develop new strategies to activate an anti-cancer immune response. Treatment based on so called checkpoint blockade, which release breaks on T-cells, are currently revolutionizing cancer therapy but the efficacy has so far been limited for treatment of AML. Today, only a limited number of molecules are explored in order to kick-start the immune response and our work aim to identify and explore novel immune cell targets for efficient treatment of AML.

By transcriptional studies (RNA sequencing), we have gained important information on T-cell populations in AML. For example, membrane receptors that can be used to activate CD8+ cytotoxic T-cells or inhibit regulatory T-cells (Tregs) are further explored to pinpoint novel potential drug targets for treatment of AML. Our in-house antibody development platform enables us to produce target-specific antibodies that can be tested functionally in in vitro assays, to identify antibodies that can activate an efficient immune response against cancer cells in AML patients.

Associate Professor Kristina Lundberg

Associate Professor Kristina Lundberg

kristina.lundberg@immun.lth.se
+46-46 222 43 23 

Department of Immunotechnology
Lund University
Medicon Village
Building 406
223 81 Lund

Page Manager: jana.hladilkova@immun.lth.se | 2021-04-09